AMD 3100, a competitive inhibitor of SDF-1, was delivered at 11 levels crossing two magnitudes, either alone or with BZM, to myeloma growing with either myeloma-associated or normal BMSC stroma. Here, CXCL12 is linked to plasma cell myeloma.